Legal / IP

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
HKG: 6628Patents

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer

Transcenta Holding Limited (HKG: 6628) announced that it has been granted an invention patent by the China National Intellectual Property Administration (CNIPA) covering the anti-CLDN18.2 antibodies independently developed by the…

Merck Loses Third Circuit Appeal as Court Upholds Medicare Drug Price Negotiations Under IRA

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US

US Merger Guidelines Updated: Public Comment Sought on Antitrust Law Changes

DiabetesGowell Pharmaceutical

Sichuan Gowell Pharmaceutical Wins Reversal in Forxiga Patent Infringement Case

Biocytogen PharmaceuticalsHKG: 2315

Biocytogen Pharmaceuticals Awarded CNIPA Patent for RenMab Human Antibody Mice Platform

CancerDiabetes

Genprex Inc. Receives Chinese Patent Protection for Reqorsa Immunogene Therapy

Show More